A Case of Melanoma of the Glans With BRAF V600E Mutation Successfully Treated With Dabrafenib and Trametinib

Key Points

• Successful treatment of melanoma involved targeted agents dabrafenib and trametinib.
• The case highlights the significance of the braf v600e mutation in therapeutic response.
• Assessment of the patient's tumor revealed responsiveness to the targeted therapy regimen.
• The implication supports the viability of specific treatments for genetic mutations in melanoma.